Background and Study Aims: When stents are placed across the esophagogastric junction for palliative treatment of malignant strictures, they may lead to esophagogastric reflux. The aim of this study was to compare the effectiveness of a newly designed antireflux stent with that of a standard open stent and a currently available antireflux stent (Dostent) in preventing gastroesophageal reflux symptoms in patients with inoperable cancer at the esophagogastric junction.Patients and Methods: Thirty-six consecutive patients with cancer at the esophagogastric junction were randomly assigned to undergo placement of a newly designed antireflux stent (n = 12), a Dostent (n = 12), or a standard open stent (n = 12). Technical and clinical success, dysphagia score, reflux symptoms, complications and ambulatory 24-h esophageal pH monitoring were assessed.Results: The technical success rates were 100 %. After 1 week, dysphagia had improved in all patient groups (P < 0.05), but the degree of improvement did not differ between the three groups. The DeMeester score was significantly lower in the group with the newly designed antireflux stent than in the other groups. The fraction of the total recording time during which esophageal pH was below 4 was 3.14 ± 5.78 % using the newly designed antireflux stent, in comparison with 29.25 ± 15.41 % in the Dostent group and 15.01 ± 11.72 % in the standard open stent group (P < 0.001). Fewer reflux episodes occurred with the newly designed antireflux stent than with the Dostent or standard open stent. There were no complications with any of the three stents.Conclusions: The newly designed antireflux stent is effective in relieving dysphagia caused by malignant cancer at the esophagogastric junction. The newly designed antireflux stent is significantly more effective in preventing gastroesophageal reflux than currently available antireflux stents.
References
-
1
Knyrim K, Wagner H J, Bethge N. et al .
A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer.
N Engl J Med.
1993;
329
1302-1307
-
2
Wu W C, Katon R M, Saxon R R. et al .
Silicone-covered self-expandable metallic stents for the palliation of malignant esophageal obstruction and esophagorespiratory fistulas: experience in 32 patients and a review of the literature.
Gastrointest Endosc.
1994;
40
22-23
-
3
Song H Y, Do Y S, Han Y M. et al .
Covered, expandable esophageal metallic stent tubes: experiences in 119 patients.
Radiology.
1994;
193
689-695
-
4
Weston A P, Sharma P.
Early and late complications from esophageal metallic stents.
Am J Gastroenterol.
1999;
94
2602
-
5
Valbuena J.
Palliation of gastroesophageal carcinoma with endoscopic insertion of a new antireflux prosthesis.
Gastrointestinal Endosc.
1984;
30
241-243
-
6
Nunes C C, Waechter F L, Sampaio J A. et al .
Comparative post-operative study of prostheses, with and without an anti-reflux valve system, in the palliative treatment of esophageal carcinoma.
Hepatogastroenterology.
1999;
46
2859-2864
-
7
Mizumoto Y, Matsuda K, Itoh Y. et al .
Trial use of a Gore-Tex covered Ultraflex stent with reflux preventive action for cardioesophageal cancer [abstract].
Gastrointest Endosc.
1997;
45
AB35
-
8
Dua K S, Koazrek R, Kim J. et al .
Self-expandable metal esophageal stent with anti-reflux mechanism.
Gastrointest Endosc.
2001;
53
603-613
-
9
Do Y S, Choo S W, Suh S W. et al .
Malignant esophagogastric junction obstruction: palliative treatment with an anti-reflux valve stent.
J Vasc Interv Radiol.
2001;
12
647-651
-
10
Shim C S, Cho Y D, Moon J H. et al .
Fixation of a modified covered esophagus stent: its clinical usefulness for preventing stent migration.
Endoscopy.
2001;
33
843-848
C. S. Shim, M.D.
Digestive Disease Center · Soon Chun Hyang University · College of Medicine
657 Hannam-Dong, Yongsan-Ku · Seoul 140-743 · South Korea
Fax: +82-2-709-9696
Email: schidr@hosp.sch.ac.kr
